



EXECUTIVE SUMMARY

September 15, 2024

K2X Technology & Life Science, Inc. (“K2X”) is a pioneering FinTech company based in Silicon Valley, offering a unique and safer way for global investors to access top-tier early-stage startups, especially in the life sciences and technology sectors. We are a new way for the world to invest in pure innovation. Here’s what sets us apart:

- **Innovative Investment Model:** K2X provides a non-correlated, high-return, low-risk, and highly liquid (assuming NASDAQ IPO completed) investment opportunity.
- **Rigorous Vetting Process:** Each investment undergoes a two-step vetting process. First, a lead investor, usually a seasoned angel group, evaluates and sets terms. Then, our panel of over 100 world-class advisors, all of whom are also investors, conducts a second review.
- **Extensive Portfolio:** K2X seeks to create an ETF-like vehicle whose assets are a large number of startups. Investing since 2018, K2X has built a portfolio with 85+ startups, 75% of which are in life sciences. Our investments span the US, Canada, Israel, and India, with plans to expand to Australia.
- **Proven Success:** Superior results, including budding unicorns and three successful exits. We anticipate an annual IRR of 20-30% measured over a number of years.
- **Investor-Friendly Structure:** K2X investors are stockholders with no annual cash calls, management fees, or carry. Ownership is straightforward—if you own 1% of K2X, you own 1% of all our assets, including future investments.
- **Aligned Interests:** Our management is only incentivized through stock options, ensuring their goals align with our investors.
- **Future Goals:** We aim to list on NASDAQ in 2024, creating “The ETF of Startups” for global investors. We’re currently raising \$5-10 million through a convertible debt round with interest and a 25% discount on the IPO conversion.

About K2X

Incorporated in Delaware, K2X focuses on creating a diversified and rigorously vetted startup portfolio, establishing a new non-correlated asset class. To date, we’ve raised \$17 million through Series A and B preferred shares, common shares, and convertible debt.

Our current portfolio includes 85+ early-stage companies in life science and technology. Our double-vetting methodology ensures we select startups most likely to succeed. Notably, our portfolio company BasePaws, acquired by Zoetis, provided a 12X return on our initial investment.

For more information on our portfolio, management, and advisory team, visit www.k2x.capital.

We have engaged bankers Ladenburg Thalmann and Northland Capital Markets to co-lead the \$50 million NASDAQ IPO and have engaged Eversheds Sutherland as the legal team. K2X is also seeking registration under the Investment Company ‘40Act, and may operate as a Business Development Company and distribute excess cash from exits, if any, quarterly to shareholders. With a proven pre-IPO business model consisting of many private investments, K2X is ready to scale up post-IPO with more, larger and later stage deals.

K2X is redefining early-stage investing!

Paul M. Russo, PhD - CEO

c: +1 (408) 605-7695
paul@k2x.capital

www.k2x.capital

Simon Westbrook - CFO

c: +1 (408) 313-5830
simon@k2x.capital